Biocartis Announces Nine Idylla Studies to be Published at Upcoming AMP 2022 Annual Meeting
Non-regulated information
Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients
Non-regulated information
Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients
Non-regulated information
Biocartis Obtains ISO 27001 Certification for Information Security Management
Non-regulated information
Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
Non-regulated information
Biocartis Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer
Non-regulated information
Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla Cartridge Sold and 2,000th Idylla Instrument Placed
Non-regulated information
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Non-regulated information
Biocartis Announces Presentation of Three Idylla Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Non-regulated information
Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference